Fundraising Fox
/Companies
Sign in

ApoGlyx

Aarhus, DK · Founded 2015 · 4 employees on LinkedIn · 2 known investors

Find your way into ApoGlyx

Each arrow is one introduction. Sign up to fill in the first one.

2 people can intro you to Michael

Ask Helen Pettersson to introduce you to Michael Rützler

You →Helen · together at ApoGlyx →Michael

Sign up to find every way you can get introduced to ApoGlyx

  • Your email: who you already know at ApoGlyx, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the ApoGlyx team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

ApoGlyx develops small-molecule aquaporin-9 inhibitors to treat severe inflammatory and metabolic diseases, including acute pancreatitis and diabetes. The company progresses its lead candidate RG210179 through clinical development and collaborates with academic institutions on drug discovery and validation.

BiotechHealthtechMedical Devices

Founders & leadership

ApoGlyx was founded in 2015 by Michael Rützler and Søren Nielsen.

MRMichael Rützler
Michael RützlerChief Executive Officer & Co-founderMichael Rützler is CEO and co-founder of ApoGlyx AB, a Lund-based company developing aquaporin inhibitors for metabolic and inflammatory diseases. He founded the company based on his academic research on aquaporin channel function and the discovery of aquaporin inhibitors.
SN
Søren NielsenCo-founder

Investors · 2

Almi InvestreportedGothenburg · $100K – $1M

How we know: funding news · nordiclifescience.org · the VCSheet dataset · Not right? Tell us

Frequently asked questions

What does ApoGlyx do?
ApoGlyx develops small-molecule aquaporin-9 inhibitors to treat severe inflammatory and metabolic diseases, including acute pancreatitis and diabetes. The company progresses its lead candidate RG210179 through clinical development and collaborates with academic institutions on drug discovery and validation.
Who founded ApoGlyx?
ApoGlyx was founded by Michael Rützler, Søren Nielsen in 2015.
Who are ApoGlyx's investors?
ApoGlyx's investors include LU Innovation, Almi Invest.
Where is ApoGlyx headquartered?
ApoGlyx is headquartered in Aarhus, DK.